Relationship between urinary sodium excretion and pioglitazone-induced edema

Journal of Diabetes Investigation

Volumn 1, Issue 5, 2010, Pages 208-211

  Nakamura, Akinobu ^a   Osonoi, Takeshi ^b   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Naka Kinen Clinic   (Japan)

Author keywords

Edema; Pioglitazone

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; PIOGLITAZONE; SODIUM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; BODY MASS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; EDEMA; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

EID: 79953749889     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00046.x     Document Type: Article

References (10)

1. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
2. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-866.
3. Kawamori R, Kadowaki T, Onji M, et al. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007; 76: 229-235.
4. Yamasue K, Tochikubo O, Kono E, et al. Self-monitoring of home blood pressure with estimation of daily salt intake using a new electrical device. J Hum Hypertens 2006; 20: 593-598.
5. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99-107.
6. Das Evcimen N, King GL. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007; 55: 498-510.
7. Emoto M, Fukuda Y, Nakamori Y, et al. Plasma concentrations of vascular endothelial growth factor are associated with peripheral edema in patients treated with thiazolidinedione. Diabetologia 2006; 49: 2217-2218.
8. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71.
9. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 66: 1279-1289.
10. Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003; 115: 111S-115S.